TGFBR1 and hepatocellular carcinoma: To investigate the molecular targets and druggable pathways for patients with HCC, we performed MACE genome-wide transcriptome sequencing and Exome-Seq all exome sequencing of tumoral (called 'tumor') and peritumoral (called 'normal') tissues extracted from tumors that had previously been shown to react differentially to TGFB1 and to the TGFBR1 inhibitor galunisertib.15